Patents by Inventor Daniel J. Sexton

Daniel J. Sexton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
    Patent number: 12384854
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: August 12, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20250199014
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: November 26, 2024
    Publication date: June 19, 2025
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK
    Publication number: 20250172567
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Application
    Filed: September 24, 2024
    Publication date: May 29, 2025
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Metabolite biomarkers for diseases associated with the contact activation system
    Patent number: 12188948
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: January 7, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
    Patent number: 12135329
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: November 5, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Compositions and methods for treatment of diabetic macular edema
    Patent number: 12084515
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 10, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA
    Publication number: 20240271211
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: December 12, 2023
    Publication date: August 15, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Diagnosis and treatment of autoimmune diseases
    Patent number: 12061206
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: August 13, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • PROTEIN BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20240142468
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: October 4, 2023
    Publication date: May 2, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20240124593
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 18, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • RNA biomarkers for hereditary angioedema
    Patent number: 11884979
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) ANDCLEAVED HMWK
    Publication number: 20230408528
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
    Patent number: 11826758
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: November 28, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Protein biomarkers for diseases associated with the contact activation system
    Patent number: 11815516
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 14, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • PLASMA KALLIKREIN BINDING PROTEINS
    Publication number: 20230340150
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: October 4, 2022
    Publication date: October 26, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Antibodies which bind Fc receptors (FcRn)
    Patent number: 11739152
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: August 29, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
    Publication number: 20230182139
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: August 23, 2022
    Publication date: June 15, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20230174674
    Abstract: Provided herein are methods for treating acute respiratory distress syndrome (ARDS), such as ARDS associated with respiratory virus infection, involving administering an inhibitor of the contact activation pathway. Also provided herein are methods for treating pneumonia and methods for reducing and/or preventing thrombosis associated with extracorporeal membrane oxygenation (ECMO) in a subject having acute respiratory distress syndrome (ARDS), involving administering an inhibitor of the contact activation pathway.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 8, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Neil Inhaber, Giorgio Giannattasio, Donatello Crocetta
  • Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
    Patent number: 11668718
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 6, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • PLASMA KALLIKREIN BINDING PROTEINS
    Publication number: 20230112931
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan